Henning Schulze-Bergkamen

Summary

Affiliation: University of Mainz
Country: Germany

Publications

  1. ncbi Novel ways to sensitise gastrointestinal cancer to apoptosis
    H Schulze-Bergkamen
    First Medical Department, University of Mainz, Langenbeckstrasse 1, D 55101 Mainz, Germany
    Gut 58:1010-24. 2009
  2. ncbi Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells
    Henning Schulze-Bergkamen
    First Department of Medicine, Johannes Gutenberg University Mainz, Mainz, Germany
    World J Gastroenterol 14:3829-40. 2008
  3. ncbi Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction
    Henning Schulze-Bergkamen
    First Department of Medicine, Johannes Gutenberg University Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany
    BMC Cancer 6:232. 2006
  4. ncbi Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma
    Binje Fleischer
    I Department of Medicine, Johannes Gutenberg University Mainz, 55101 Mainz, Germany
    Int J Oncol 28:25-32. 2006
  5. ncbi TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies
    Bruno Christian Koehler
    First Department of Medicine, Johannes Gutenberg University Mainz, 55101 Mainz, Germany
    World J Gastroenterol 15:5924-35. 2009
  6. ncbi Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes
    Binje Vick
    1st Department of Medicine, Johannes Gutenberg University Mainz, Germany
    Hepatology 49:627-36. 2009
  7. ncbi IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53
    Kerstin Herzer
    Department of Medicine, Johannes Gutenberg University, Mainz, Germany
    Cancer Res 69:855-62. 2009
  8. ncbi Genetics of hepatocellular carcinoma
    Andreas Teufel
    Department of Medicine, Johannes Gutenberg University, Building 301, Langenbeckstr 1, 55101 Mainz, Germany
    World J Gastroenterol 13:2271-82. 2007
  9. ncbi Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells
    Toni Urbanik
    First Department of Medicine, Johannes Gutenberg University, Mainz, Germany
    Int J Oncol 38:121-31. 2011
  10. ncbi Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis
    Marcus Alexander Wörns
    I Department of Internal Medicine, Johannes Gutenberg University Mainz, Germany
    J Clin Gastroenterol 43:489-95. 2009

Collaborators

  • Andreas Teufel
  • Achim Weber
  • Markus Moehler
  • Thomas G Hofmann
  • Stefan Biesterfeld
  • Marcus Schuchmann
  • Toni Urbanik
  • Peter R Galle
  • Marcus Alexander Wörns
  • Binje Vick
  • Regina Johanna Boger
  • Peter Robert Galle
  • Steffen Heeger
  • Gerd Otto
  • Stephan Kanzler
  • Kerstin Herzer
  • Bruno Christian Koehler
  • Peter H Krammer
  • Binje Fleischer
  • Bruno Christian Köhler
  • Nadine Hövelmeyer
  • Ari Waisman
  • Kerstin Pfingst
  • Thorsten Maass
  • Carla Schulte-Sasse
  • Christoph C Schimanski
  • Claudia Martina Messow
  • Joseph T Opferman
  • Arndt Weinmann
  • Christoph Duber
  • Martina Müller

Detail Information

Publications11

  1. ncbi Novel ways to sensitise gastrointestinal cancer to apoptosis
    H Schulze-Bergkamen
    First Medical Department, University of Mainz, Langenbeckstrasse 1, D 55101 Mainz, Germany
    Gut 58:1010-24. 2009
    ..In this review, the current knowledge on defects in apoptosis signalling in GI cancer is summarised and the focus is on the potential clinical efficacy of apoptosis targeting agents...
  2. ncbi Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells
    Henning Schulze-Bergkamen
    First Department of Medicine, Johannes Gutenberg University Mainz, Mainz, Germany
    World J Gastroenterol 14:3829-40. 2008
    ..To explore the role of Bcl-x(L) and Myeloid cell leukaemia (Mcl)-1 for the apoptosis resistance of colorectal carcinoma (CRC) cells towards current treatment modalities...
  3. ncbi Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction
    Henning Schulze-Bergkamen
    First Department of Medicine, Johannes Gutenberg University Mainz, Langenbeckstrasse 1, 55101 Mainz, Germany
    BMC Cancer 6:232. 2006
    ..In this study, we manipulated expression of the Mcl-1 protein in HCC cells by RNA interference and analyzed its impact on apoptosis sensitivity of HCC cells in vitro...
  4. ncbi Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma
    Binje Fleischer
    I Department of Medicine, Johannes Gutenberg University Mainz, 55101 Mainz, Germany
    Int J Oncol 28:25-32. 2006
    ..Our data suggest that Mcl-1 is an important factor for the apoptosis resistance of human HCC, and constitutes an interesting target for HCC therapy...
  5. ncbi TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies
    Bruno Christian Koehler
    First Department of Medicine, Johannes Gutenberg University Mainz, 55101 Mainz, Germany
    World J Gastroenterol 15:5924-35. 2009
    ....
  6. ncbi Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes
    Binje Vick
    1st Department of Medicine, Johannes Gutenberg University Mainz, Germany
    Hepatology 49:627-36. 2009
    ..Conclusion: The present study provides in vivo evidence that Mcl-1 is a crucial antiapoptotic factor for the liver, contributing to hepatocellular homeostasis and protecting hepatocytes from apoptosis induction...
  7. ncbi IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53
    Kerstin Herzer
    Department of Medicine, Johannes Gutenberg University, Mainz, Germany
    Cancer Res 69:855-62. 2009
    ....
  8. ncbi Genetics of hepatocellular carcinoma
    Andreas Teufel
    Department of Medicine, Johannes Gutenberg University, Building 301, Langenbeckstr 1, 55101 Mainz, Germany
    World J Gastroenterol 13:2271-82. 2007
    ..Furthermore, we describe the influence of chromosomal aberrations as well as of DNA methylation. Finally, we report on the rapidly developing field of genomic expression profiling in HCC, mainly by microarray analysis...
  9. ncbi Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells
    Toni Urbanik
    First Department of Medicine, Johannes Gutenberg University, Mainz, Germany
    Int J Oncol 38:121-31. 2011
    ..Our data identify the reconstitution of CYLD expression as an attractive approach for overcoming resistance to treatment in HCC...
  10. ncbi Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis
    Marcus Alexander Wörns
    I Department of Internal Medicine, Johannes Gutenberg University Mainz, Germany
    J Clin Gastroenterol 43:489-95. 2009
    ..We report our experiences with sorafenib in advanced HCC, particularly in patients with LCI Child-Pugh B/C, where only limited data are available in regard to safety and efficacy of sorafenib...
  11. ncbi The role of apoptosis versus oncotic necrosis in liver injury: facts or faith?
    Henning Schulze-Bergkamen
    Department of Medicine, Johannes Gutenberg University, Langenbeckstrasse 1, Mainz 55101, Germany
    J Hepatol 44:984-93. 2006